|
Gene: TPP1 |
Gene summary for TPP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TPP1 | Gene ID | 1200 |
Gene name | tripeptidyl peptidase 1 | |
Gene Alias | CLN2 | |
Cytomap | 11p15.4 | |
Gene Type | protein-coding | GO ID | GO:0001894 | UniProtAcc | O14773 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1200 | TPP1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.41e-09 | 4.39e-01 | -0.1808 |
1200 | TPP1 | HTA11_347_2000001011 | Human | Colorectum | AD | 8.07e-12 | 3.49e-01 | -0.1954 |
1200 | TPP1 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.87e-02 | 2.36e-01 | -0.1526 |
1200 | TPP1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.32e-05 | 3.09e-01 | -0.059 |
1200 | TPP1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 2.42e-02 | 3.16e-01 | -0.1462 |
1200 | TPP1 | HTA11_866_3004761011 | Human | Colorectum | AD | 6.14e-09 | 3.37e-01 | 0.096 |
1200 | TPP1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.40e-05 | 2.64e-01 | 0.294 |
1200 | TPP1 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 3.01e-10 | 3.92e-01 | 0.281 |
1200 | TPP1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.01e-12 | 4.00e-01 | 0.3859 |
1200 | TPP1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.08e-02 | 1.95e-01 | 0.2585 |
1200 | TPP1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.11e-03 | 1.97e-01 | 0.3005 |
1200 | TPP1 | LZE4T | Human | Esophagus | ESCC | 8.73e-04 | 2.18e-01 | 0.0811 |
1200 | TPP1 | LZE7T | Human | Esophagus | ESCC | 1.18e-09 | 2.82e-01 | 0.0667 |
1200 | TPP1 | LZE8T | Human | Esophagus | ESCC | 1.55e-06 | 1.48e-01 | 0.067 |
1200 | TPP1 | LZE20T | Human | Esophagus | ESCC | 2.82e-02 | -3.85e-03 | 0.0662 |
1200 | TPP1 | LZE22D1 | Human | Esophagus | HGIN | 1.16e-02 | -1.66e-02 | 0.0595 |
1200 | TPP1 | LZE22T | Human | Esophagus | ESCC | 7.75e-06 | 1.29e-01 | 0.068 |
1200 | TPP1 | LZE24T | Human | Esophagus | ESCC | 1.12e-20 | 6.31e-01 | 0.0596 |
1200 | TPP1 | LZE21T | Human | Esophagus | ESCC | 3.29e-03 | 7.45e-02 | 0.0655 |
1200 | TPP1 | P1T-E | Human | Esophagus | ESCC | 3.95e-07 | 2.19e-01 | 0.0875 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070332 | Liver | Cirrhotic | vacuole organization | 80/4634 | 180/18723 | 5.73e-09 | 2.25e-07 | 80 |
GO:007149612 | Liver | Cirrhotic | cellular response to external stimulus | 123/4634 | 320/18723 | 3.27e-08 | 1.10e-06 | 123 |
GO:00316686 | Liver | Cirrhotic | cellular response to extracellular stimulus | 96/4634 | 246/18723 | 4.55e-07 | 1.05e-05 | 96 |
GO:00701982 | Liver | Cirrhotic | protein localization to chromosome, telomeric region | 19/4634 | 29/18723 | 4.10e-06 | 6.90e-05 | 19 |
GO:0007040 | Liver | Cirrhotic | lysosome organization | 35/4634 | 74/18723 | 2.10e-05 | 2.77e-04 | 35 |
GO:0080171 | Liver | Cirrhotic | lytic vacuole organization | 35/4634 | 74/18723 | 2.10e-05 | 2.77e-04 | 35 |
GO:00196922 | Liver | Cirrhotic | deoxyribose phosphate metabolic process | 23/4634 | 42/18723 | 2.97e-05 | 3.75e-04 | 23 |
GO:00093942 | Liver | Cirrhotic | 2'-deoxyribonucleotide metabolic process | 22/4634 | 40/18723 | 4.04e-05 | 4.82e-04 | 22 |
GO:00092622 | Liver | Cirrhotic | deoxyribonucleotide metabolic process | 23/4634 | 44/18723 | 7.87e-05 | 8.61e-04 | 23 |
GO:0009219 | Liver | Cirrhotic | pyrimidine deoxyribonucleotide metabolic process | 15/4634 | 24/18723 | 9.76e-05 | 1.03e-03 | 15 |
GO:1901292 | Liver | Cirrhotic | nucleoside phosphate catabolic process | 36/4634 | 83/18723 | 1.54e-04 | 1.47e-03 | 36 |
GO:0009264 | Liver | Cirrhotic | deoxyribonucleotide catabolic process | 17/4634 | 30/18723 | 1.87e-04 | 1.74e-03 | 17 |
GO:00091662 | Liver | Cirrhotic | nucleotide catabolic process | 32/4634 | 73/18723 | 2.78e-04 | 2.46e-03 | 32 |
GO:0006220 | Liver | Cirrhotic | pyrimidine nucleotide metabolic process | 24/4634 | 50/18723 | 3.06e-04 | 2.68e-03 | 24 |
GO:0046386 | Liver | Cirrhotic | deoxyribose phosphate catabolic process | 17/4634 | 31/18723 | 3.19e-04 | 2.77e-03 | 17 |
GO:0009223 | Liver | Cirrhotic | pyrimidine deoxyribonucleotide catabolic process | 12/4634 | 19/18723 | 4.35e-04 | 3.55e-03 | 12 |
GO:00091416 | Liver | Cirrhotic | nucleoside triphosphate metabolic process | 43/4634 | 112/18723 | 9.31e-04 | 6.62e-03 | 43 |
GO:0006244 | Liver | Cirrhotic | pyrimidine nucleotide catabolic process | 12/4634 | 21/18723 | 1.53e-03 | 9.98e-03 | 12 |
GO:0034502 | Liver | Cirrhotic | protein localization to chromosome | 36/4634 | 92/18723 | 1.58e-03 | 1.03e-02 | 36 |
GO:0007039 | Liver | Cirrhotic | protein catabolic process in the vacuole | 11/4634 | 19/18723 | 2.09e-03 | 1.29e-02 | 11 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04142 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa041421 | Colorectum | SER | Lysosome | 38/1580 | 132/8465 | 2.87e-03 | 2.03e-02 | 1.47e-02 | 38 |
hsa041426 | Esophagus | HGIN | Lysosome | 33/1383 | 132/8465 | 6.65e-03 | 4.37e-02 | 3.47e-02 | 33 |
hsa0414213 | Esophagus | HGIN | Lysosome | 33/1383 | 132/8465 | 6.65e-03 | 4.37e-02 | 3.47e-02 | 33 |
hsa0414222 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa0414232 | Esophagus | ESCC | Lysosome | 102/4205 | 132/8465 | 5.11e-11 | 7.13e-10 | 3.65e-10 | 102 |
hsa041424 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
hsa0414211 | Liver | Cirrhotic | Lysosome | 68/2530 | 132/8465 | 1.34e-07 | 1.97e-06 | 1.21e-06 | 68 |
hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa041425 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0414212 | Oral cavity | OSCC | Lysosome | 87/3704 | 132/8465 | 1.97e-07 | 1.35e-06 | 6.86e-07 | 87 |
hsa0414221 | Oral cavity | LP | Lysosome | 67/2418 | 132/8465 | 5.13e-08 | 7.77e-07 | 5.01e-07 | 67 |
hsa0414231 | Oral cavity | LP | Lysosome | 67/2418 | 132/8465 | 5.13e-08 | 7.77e-07 | 5.01e-07 | 67 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TPP1 | SNV | Missense_Mutation | c.508G>A | p.Val170Met | p.V170M | O14773 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
TPP1 | SNV | Missense_Mutation | c.1514N>T | p.Pro505Leu | p.P505L | O14773 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | |
TPP1 | SNV | Missense_Mutation | novel | c.312N>T | p.Leu104Phe | p.L104F | O14773 | protein_coding | deleterious(0.05) | benign(0.165) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
TPP1 | SNV | Missense_Mutation | rs149529997 | c.1526N>G | p.Gln509Arg | p.Q509R | O14773 | protein_coding | tolerated(0.12) | benign(0) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
TPP1 | SNV | Missense_Mutation | rs778410642 | c.802N>T | p.Arg268Trp | p.R268W | O14773 | protein_coding | deleterious(0.02) | possibly_damaging(0.812) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TPP1 | SNV | Missense_Mutation | rs769487055 | c.1279A>T | p.Thr427Ser | p.T427S | O14773 | protein_coding | tolerated(0.84) | benign(0) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
TPP1 | SNV | Missense_Mutation | rs368914445 | c.1123C>T | p.Arg375Cys | p.R375C | O14773 | protein_coding | tolerated(0.06) | probably_damaging(0.99) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TPP1 | SNV | Missense_Mutation | rs140176031 | c.776N>A | p.Arg259His | p.R259H | O14773 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-AA-A024-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TPP1 | SNV | Missense_Mutation | c.1157N>A | p.Thr386Asn | p.T386N | O14773 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
TPP1 | SNV | Missense_Mutation | c.800N>C | p.Gly267Ala | p.G267A | O14773 | protein_coding | tolerated(0.13) | benign(0.14) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1200 | TPP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | Cerliponase Alfa | |||
1200 | TPP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | cerliponase alfa | |||
1200 | TPP1 | PROTEASE, ENZYME, DRUGGABLE GENOME | Cerliponase Alfa |
Page: 1 |